Bazedoxifene and Conjugated Estrogens for Breast Cancer
Study Summary
This trial is testing whether taking a combination of bazedoxifene and conjugated estrogens for six months can help reduce risk factors for breast cancer development.
- Breast Cancer
- Risk Reduction
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
What is the scope of the population being treated through this research study?
"As per the inclusion criteria, 120 eligible participants are needed for this trial. The two main locations open to enrolling patients are Northwestern Medical Center in Chicago and Dana Farber Cancer Institute in Boston."
Has the FDA granted approval for Bazedoxifene and Conjugated Estrogens?
"Bazedoxifene and Conjugated Estrogens have been evaluated in a Phase 2 trial, so their safety is estimated to be a score of 2 on the 1-3 scale. This implies that there are some data points supporting safety but none demonstrating efficacy."
How many venues are providing access to this research?
"This medical study is welcoming participants at Northwestern Medical Center in Chicago, IL; Dana Farber Cancer Institute in Boston, MA; University of Kansas Medical Center in Kansas City, KS as well as 5 other sites."
To which conditions does the Bazedoxifene and Conjugated Estrogens combination provide relief?
"Bazedoxifene and Conjugated Estrogens can be utilized to alleviate premature menopause as well as other conditions such as female castration, vasomotor dysfunction, and the cessation of menses."
Could you elaborate on any prior experiments that have utilized Bazedoxifene and Conjugated Estrogens?
"Bazedoxifene and Conjugated Estrogens research began in 2013 at UTMB Speciality Care Center at Victory Lakes, with 53 studies completed to date. Currently 15 active trials are taking place around the world, particularly concentrated within Chicago, Illinois."
Is enrollment open for this research trial?
"According to the data on clinicaltrials.gov, this trial is presently enrolling members. This medical experiment was initially published on December 14th 2021 and its details were last modified February 14th 2022."
Does this investigation permit minors to participate?
"Qualifying patients for this clinical study must be aged 45 to 60. Conversely, there are 78 trials directed at minors and an abundance of studies available (2538) for seniors over 65."
Do I meet the eligibility criteria to join this research endeavor?
"This clinical trial seeks to enroll 120 patients with risk reduction, aged 45-60 years old. The inclusion criteria includes current vasomotor symptoms (hot flashes, night sweats or both) at least once a week, one of four menopausal status categories and BMI ≤ 35 kg/m2. Furthermore, participants must have an intact uterus if within age 45 - 60 and either possess an ovary or had their FSH tested as ≥ 25 mIU/ml in the postmenopausal range by institutional laboratory standards for those between ages 45-49."